Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 500,000 incident cancers worldwide. The treatment of HNSCC, combinations of surgery, radiation and chemotherapy, often result in significant morbidity and substantial healthcare costs. Elimination of the initial tumor offers the best chance of cure, yet we succeed only 50 percent of the time. Therapy fails most often due to recurrence at the primary site or in the neck, and less often from distant metastases. When initial or recurrent tumors are identified early, treatment outcome is better. Unfortunately the majority of HNSCC are identified in later stage. A marker for HNSCC that is able to detect new cancers and recurrences in early stages would be useful. CD44 may be a molecular marker of malignancy in other tissues and is detectable in body fluids in soluble form (solCD44). Our preliminary data suggest that solCD44 is increased in the saliva of HNSCC tumor patients compared to controls. In this study we will examine the expression of solCD44 in both newly diagnosed HNSCC patients and controls and in HNSCC patients with recurrence or second primaries. We will use a solCD44 ELISA test and a protein assay to evaluate the expression of solCD44 in HNSCC patient's saliva (aim 1). We will compare these to sol CD44 levels in controls that are matched for age, sex, race, socioeconomic status, tobacco and alcohol use. We will use the same assays to evaluate the expression of solCD44 in patients with recurrent or second primary HNSCC matching for previous treatment, original stage, tobacco and alcohol use (aim 2). The results of these studies will determine the validity of soICD44 ELISA test as a screening test for HNSCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
1R03CA107828-01
Application #
6783728
Study Section
Special Emphasis Panel (ZCA1-SRRB-Q (J1))
Program Officer
Krueger, Karl E
Project Start
2004-03-01
Project End
2006-02-28
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
1
Fiscal Year
2004
Total Cost
$75,750
Indirect Cost
Name
University of Miami School of Medicine
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
052780918
City
Miami
State
FL
Country
United States
Zip Code
33146
Pereira, Lutécia H Mateus; Reis, Isildinha M; Reategui, Erika P et al. (2016) Risk Stratification System for Oral Cancer Screening. Cancer Prev Res (Phila) 9:445-55
Franzmann, Elizabeth J; Reategui, Erika P; Pereira, Lutecia H Mateus et al. (2012) Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck 34:687-95
Pereira, Lutécia H Mateus; Adebisi, Islamiyat Nancy; Perez, Aymee et al. (2011) Salivary markers and risk factor data: a multivariate modeling approach for head and neck squamous cell carcinoma detection. Cancer Biomark 10:241-9
Franzmann, Elizabeth J; Reategui, Erika P; Pedroso, Felipe et al. (2007) Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 16:1348-55
Franzmann, Elizabeth J; Reategui, Erika P; Carraway, Kermit L et al. (2005) Salivary soluble CD44: a potential molecular marker for head and neck cancer. Cancer Epidemiol Biomarkers Prev 14:735-9